Puma Biotechnology Inc. (PBYI)’s Financial Results Comparing With Seres Therapeutics Inc. (NASDAQ:MCRB)

This is therefore a contrasting of the risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation in Puma Biotechnology Inc. (NASDAQ:PBYI) and Seres Therapeutics Inc. (NASDAQ:MCRB). The two are both Biotechnology companies that compete with one another.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Puma Biotechnology Inc. 250.99M 6.03 113.58M -3.90 0.00
Seres Therapeutics Inc. 28.27M 9.58 98.94M -2.62 0.00

Table 1 showcases the gross revenue, earnings per share (EPS) and valuation of Puma Biotechnology Inc. and Seres Therapeutics Inc.


Table 2 demonstrates the return on equity, return on assets and net margins of Puma Biotechnology Inc. and Seres Therapeutics Inc.

Net Margins Return on Equity Return on Assets
Puma Biotechnology Inc. -45.25% -430.7% -105.8%
Seres Therapeutics Inc. -349.98% 0% -72.2%

Volatility and Risk

Puma Biotechnology Inc. is 36.00% less volatile than Standard and Poor’s 500 because the stock has a beta of 0.64. Competitively, Seres Therapeutics Inc.’s beta is 1.79 which is 79.00% more volatile than Standard and Poor’s 500.


The current Quick Ratio of Puma Biotechnology Inc. is 3 while its Current Ratio is 3. Meanwhile, Seres Therapeutics Inc. has a Current Ratio of 2 while its Quick Ratio is 2. Puma Biotechnology Inc. is better positioned to pay off its short-term and long-term debts than Seres Therapeutics Inc.

Analyst Ratings

Puma Biotechnology Inc. and Seres Therapeutics Inc. Ratings and Recommendations are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Puma Biotechnology Inc. 0 0 0 0.00
Seres Therapeutics Inc. 0 0 4 3.00

Seres Therapeutics Inc. on the other hand boasts of a $14 average price target and a 112.12% potential upside.

Institutional & Insider Ownership

Puma Biotechnology Inc. and Seres Therapeutics Inc. has shares owned by institutional investors as follows: 94.9% and 78%. Insiders owned 11.3% of Puma Biotechnology Inc. shares. Insiders Comparatively, owned 1.2% of Seres Therapeutics Inc. shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Puma Biotechnology Inc. 40.09% 43.76% 74.41% -3.88% -35.09% 96.95%
Seres Therapeutics Inc. 5.72% 1.95% -25.06% -27.06% -34.17% 38.94%

For the past year Puma Biotechnology Inc.’s stock price has bigger growth than Seres Therapeutics Inc.


Seres Therapeutics Inc. beats Puma Biotechnology Inc. on 6 of the 11 factors.

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to improve cancer care. Its drug candidates include PB272 (neratinib (oral)) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 (neratinib (intravenous)). The company also develops PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of PB272 neratinib (oral), PB272 neratinib (intravenous), PB357, and certain related compounds. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.

Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. Its lead product candidate is SER-109, a bacterial spore ecology, which has completed Phase II clinical study to treat multiply recurrent Clostridium difficile infection (CDI). The company also develops SER-287 that is in Phase Ib clinical study in patients with mild-to-moderate ulcerative colitis; and SER-262, a synthetic microbiome therapeutic candidate, which is in Phase Ib study in patients with primary CDI. Its product candidates in pre-clinical development comprise SER-301, a synthetic Ecobiotic microbiome therapeutic candidate for the treatment of inflammatory bowel disease; and SER-155, an Ecobiotic microbiome therapeutic for the prevention of transplant-related mortality. Seres Therapeutics, Inc. has a strategic collaboration with Nestle Health Science and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.


Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.